Testicular cancer suspicion — UKMLA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Tisotumab vedotin
The best answer is “Tisotumab vedotin”. Tisotumab vedotin is commissioned for recurrent or metastatic cervical cancer that has progressed on or after systemic treatment. The other antibody–drug conjugates have superficially similar names but different targets and tumour settings: FR-alpha-positive ovarian cancer, BCMA-positive myeloma, selected HER2-expressing tumours and urothelial cancer. Recognising the tissue-factor-directed cervical-cancer agent avoids a common class-name substitution error.
Reference: NICE TA1164, Tisotumab vedotin for recurrent or metastatic cervical cancer: https://www.nice.org.uk/guidance/ta1164/chapter/1-Recommendations